Kazuko Kaneda-Nakashima

Prof. Kazuko Kaneda-Nakashima

Graduate School of Science, Osaka University, Ōsaka, Japan
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
TWTadashi Watabe
Tadashi Watabe
YLYuwei Liu
Yuwei Liu
Kazuko Kaneda-NakashimaKazuko Kaneda-Nakashima
Kazuko Kaneda-Nakashima
YSYoshifumi Shirakami
Yoshifumi Shirakami
TLThomas Lindner
Thomas Lindner
JHJun Hatazawa
Jun Hatazawa
Fibroblast activation protein (FAP), which promotes tumor growth and progression, is overexpressed in cancer-associated fibroblasts of many human epithelial cancers. Because of its low expression in normal organs, FAP is an excellent target for theranostics. In this study, we used radionuclides with relatively long half-lives, 64Cu (half-life, 12.7 h) and 225Ac (half-life, 10 d), to label FAP inhibitors (FAPIs) in mice with human pancreatic cancer xenografts. Methods: Male nude mice (body weight, 22.5 ± 1.2 g) were subcutaneously injected with human pancreatic cancer cells (PANC-1, n = 12; MIA PaCa-2, n = 8). Tumor xenograft mice were investigated after the intravenous injection of 64Cu-FAPI-04 (7.21 ± 0.46 MBq) by dynamic and delayed PET scans (2.5 h after injection). Static scans 1 h after the injection of 68Ga-FAPI-04 (3.6 ± 1.4 MBq) were also acquired for comparisons using the same cohort of mice (n = 8). Immunohistochemical staining was performed to confirm FAP expression in tumor xenografts using an FAP-α-antibody. For radioligand therapy, 225Ac-FAPI-04 (34 kBq) was injected into PANC-1 xenograft mice (n = 6). Tumor size was monitored and compared with that of control mice (n = 6). Results: Dynamic imaging of 64Cu-FAPI-04 showed rapid clearance through the kidneys and slow washout from tumors. Delayed PET imaging of 64Cu-FAPI-04 showed mild uptake in tumors and relatively high uptake in the liver and intestine. Accumulation levels in the tumor or normal organs were significantly higher for 64Cu-FAPI-04 than for 68Ga-FAPI-04, except in the heart, and excretion in the urine was higher for 68Ga-FAPI-04 than for 64Cu-FAPI-04. Immunohistochemical staining revealed abundant FAP expression in the stroma of xenografts. 225Ac-FAPI-04 injection showed significant tumor growth suppression in the PANC-1 xenograft mice, compared with the control mice, without a significant change in body weight. Conclusion: This proof-of-concept study showed that 64Cu-FAPI-04 and 225Ac-FAPI-04 could be used in theranostics for the treatment of FAP-expressing pancreatic cancer. α-therapy targeting FAP in the cancer stroma is effective and will contribute to the development of a new treatment strategy.

23 August 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MSMakiko Shimizu
Makiko Shimizu
AMAkira Matsuda
Akira Matsuda
KYKen Yanagisawa
Ken Yanagisawa
THTomomitsu Hirota
Tomomitsu Hirota
MAMitsuteru Akahoshi
Mitsuteru Akahoshi
TSTaro Shirakawa
Taro Shirakawa
Atopic dermatitis (AD) is a common inflammatory skin disease associated with the local infiltration of T helper type 2 (Th2) cells. The ST2 gene encodes both membrane-bound ST2L and soluble ST2 (sST2) proteins by alternative splicing. The orphan receptor ST2L is functionally indispensable for Th2 cells. We found a significant genetic association between AD and the −26999G/A single nucleotide polymorphism (SNP) (χ2-test, raw P-value=0.000007, odds ratio 1.86) in the distal promoter region of the ST2 gene (chromosome 2q12) in a study of 452 AD patients and 636 healthy controls. The −26999A allele common among AD patients positively regulates the transcriptional activity of the ST2 gene. In addition, having at least one −26999A allele correlated with high sST2 concentrations and high total IgE levels in the sera from AD patients. Thus, the −26999A allele is correlated with an increased risk for AD. We also found that the −26999G/A SNP predominantly affected the transcriptional activity of hematopoietic cells. Immunohistochemical staining of a skin biopsy specimen from an AD patient in the acute stage showed ST2 staining in the keratinocytes as well as in the infiltrating cells in the dermal layer. Our data show that functional SNPs in the ST2 distal promoter region regulate ST2 expression which induces preferential activation of the Th2 response. Our findings will contribute to the evaluation of one of the genetic risk factors for AD.

1 April 2007 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
MHMichishige Harada
Michishige Harada
Kazuko Kaneda-NakashimaKazuko Kaneda-Nakashima
Kazuko Kaneda-Nakashima
THTomomitsu Hirota
Tomomitsu Hirota
MSMakiko Shimizu
Makiko Shimizu
SDSatoru Doi
Satoru Doi
MTMayumi Tamari
Mayumi Tamari
Suppressor of cytokine signaling (SOCS) 1 is an essential physiologic regulator of the IFN-γ signaling that is crucial to lead appropriate immune responses, and impaired IFN-γ production is considered a hallmark of atopic diseases. Recent study has shown that SOCS1 is also crucial in attenuating type 1 IFN signaling and in limiting the host response to viral infection. Clinical and experimental evidence suggest an important role for respiratory viral infections in the development of asthma. To assess genetic functional variants of SOCS1 related to susceptibility and clinical phenotypes in adult asthma in a Japanese population, we conducted association and haplotype analyses of 462 subjects with adult asthma and 639 control subjects. After screening for polymorphisms, we identified a total of 13 variants and characterized the linkage disequilibrium (LD) mapping of the gene. Three variants were selected for genotyping with regard to the LD pattern, and we found a significant association between an SOCS1 promoter polymorphism −1478CA > del and adult asthma (P = 0.0063). The three-locus haplotype of SOCS1 using these three polymorphisms also showed a positive association with a haplotype T-C-del (−5388T, −3969C, and −1478 del; P = 0.0097). Furthermore, reporter gene analysis revealed that related promoter variant −1478 del enhanced the transcriptional level of SOCS1 in human lung epithelial cells, and induced higher levels of protein expression of SOCS1 and lower phosphorylation of STAT1 stimulated with IFN-β. These findings suggest that the SOCS1 gene might be involved in the development of adult asthma through functional genetic polymorphism.

22 February 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
TWTadashi Watabe
Tadashi Watabe
Kazuko Kaneda-NakashimaKazuko Kaneda-Nakashima
Kazuko Kaneda-Nakashima
YLYuwei Liu
Yuwei Liu
YSYoshifumi Shirakami
Yoshifumi Shirakami
KOKazuhiro Ooe
Kazuhiro Ooe
JHJun Hatazawa
Jun Hatazawa
211At is an α-emitter that has similar chemical properties to iodine and is used in targeted α-therapy. In the present study, we added ascorbic acid (AA) to 211At solution to increase the radiochemical purity of astatide and evaluated its efficacy against differentiated thyroid cancer, which is characterized by the expression of sodium/iodide symporter (NIS). Methods: Crude 211At solution (AA(−)) and 211At solution treated with AA (AA(+)) were prepared. Uptake by the thyroid was compared between the 2 solutions in normal male Wistar rats (n = 6). Cellular uptake in K1-NIS cells was analyzed under the AA(+) and AA(−) conditions. AA(+) was injected at 3 doses into K1-NIS xenograft mice: 1 MBq (n = 6), 0.4 MBq (n = 6), and 0.1 MBq (n = 6), and vehicle was injected into control mice (n = 6). The treatment effects were compared among the 4 groups. Results: Uptake by the thyroid was significantly enhanced in rats injected with the AA(+) as compared with those injected with AA(−). Cellular uptake analysis showed significantly increased uptake of 211At by the K1-NIS cells under the AA(+) condition as compared with the AA(−) condition. In the mouse xenograft model, the K1-NIS tumors showed significant accumulation of 211At at 3 and 24 h after administration (22.5 ± 10.4 and 12.9 ± 6.8 percentage injected dose, respectively). Tumor growth was immediately inhibited in a dose-dependent manner after administration of 211At. In the survival analysis, the 211At groups (0.1, 0.4, and 1 MBq) showed significantly better survival than the control group. Conclusion: Uptake of 211At was enhanced in differentiated thyroid cancer cells as well as the normal thyroid using 211At solution treated with AA. The method also showed dose-dependent efficacy against the K1-NIS xenografts, suggesting its potential applicability to targeted α-therapy.

1 August 2007 in Human Gene Therapy
Verified
Journal Article
Closed access
TYTomoko Yamaguchi
Tomoko Yamaguchi
KKKenji Kawabata
Kenji Kawabata
NKNaoya Koizumi
Naoya Koizumi
FSFuminori Sakurai
Fuminori Sakurai
Kazuko Kaneda-NakashimaKazuko Kaneda-Nakashima
Kazuko Kaneda-Nakashima
HMHiroyuki Mizuguchi
Hiroyuki Mizuguchi
A replication-incompetent adenoviral (Ad) vector is generating interest for both gene therapy and immunotherapy. A major limitation of the use of Ad vectors is the innate immune response, which causes inflammatory cytokine production and tissue damage; however, the precise mechanism of the innate immune response remains to be clarified. Here, we show that serotype 5 human Ad vectors elicit innate immune responses through a myeloid differentiating factor 88 (MyD88)/Toll-like receptor (TLR)-9-dependent and/or -independent manner according to cell type. After stimulation with Ad vectors, the production of interleukin (IL)-6 and IL-12 was significantly decreased in MyD88- or TLR9-deficient dendritic cells (DCs), compared with wild-type DCs. In addition, the surface expression of maturation marker proteins, such as CD40, CD80, CD86, and MHC class II, in MyD88- or TLR9-deficient granulocyte-macrophage colony-stimulating factor (GM-CSF)-DCs was similar to that in wild-type DCs. On the other hand, MyD88- or TLR9-deficient peritoneal macrophages produced the same level of IL-6 as wild-type macrophages after infection with Ad vectors. We did not find any differences in the mRNA expression levels of the molecules involved in innate immunity, such as MyD88, TLR3, TLR7, and TLR9, between DCs and macrophages. The intravenous injection of luciferase-expressing Ad vectors into MyD88- or TLR9-deficient mice resulted in almost comparable levels of IL-6 and IL-12 production and luciferase expression with wild-type mice. These results suggest that Ad vectors can activate innate immunity via MyD88/TLR9-dependent and -independent mechanisms.

5 March 2004 in Human Genetics
Verified
Journal Article
Closed access
PDF file
MAMitsuteru Akahoshi
Mitsuteru Akahoshi
MIMami Ishihara
Mami Ishihara
NRNatascha Remus
Natascha Remus
KUKazuko Uno
Kazuko Uno
KMKatsuhisa Miyake
Katsuhisa Miyake
TSTaro Shirakawa
Taro Shirakawa